## **Cabenuva/Apretude Enrollment Form**



Fax Referral To: 1-855-297-1270

Phone: 1-888-280-1190 Address: 280 Avenida Jesus T. Pinero Ste B Rio, PR 00927 NCPDP: 4026325

|  | Six Simple Steps to Su   | ubmitting a Referra  | al  |
|--|--|--|---|
| PATIENT INFORMATION (Page 1)   | atient must complete highlight   | ed area) <b>Scheduled</b>  | Injection Date:   |
| Patient Name:  | Add  | ress:  |   |
| City, State, ZIP Code:   | DOB:   | Last Four of SS  | SN: Gender: 🗌 Male 🔲 Female   |
| Primary Phone:   | Alternate Phone:   | Ema  | il:   |
| prescription(s), account and health care. Standa<br>Note: Carrier charges may apply. By providing th<br>from CVS Specialty® about your prescription(s),<br>Specialty Pharmacy will attempt to contact by p | ard data rates apply. Message frequency<br>he phone number(s) and email address a<br>account, and health care. Standard data               | varies.<br>bove, you are consenting to re  | d/or text messages from CVS Specialty® about your ceive automated calls, emails and/or text messages cy varies. If unable to contact via text or email,           |
| Designated Patient Contact   | taat listed balow to receive les   | victical and administrativ   | us information related to my treatment  |
| including ability to make decisions on   | my behalf, for which I will remaion) or Apretude (cabotegravir e   | ain liable, regarding del<br>extended-release inject                               | ve information related to my treatment, ivery of Cabenuva (cabotegravir/rilpivirine table suspension). CVS Specialty is not decisions. Please list any authorized |
|  |  | Relationship:  | Phone:  |
|  |  |  |   |
| Patient's Signature:   | ·  |  | Date:   |
| Patient Authorization  |  |  |   |
| my Cabenuva or Apretude prescription scheduled appointment. I understand will not outreach/contact me and/or   | on medication for the sole purpor<br>d that my signature below serve<br>my designated contact on this<br>bay to CVS Specialty any required | ose of administration by<br>es as the Patient Ship Au<br>form, prior to shipping r | uthorization, which means the pharmacy  |
|  | 9  |  |   |
|  | tient's designee in the event the patient's<br>cause government payors are excluded  | from this offering. Copayment,   | Date:   |
| PRESCRIBER INFORMATION   | N  |  |   |
| Facility Type:  Private Practice   |  | c ☐ Other:   |   |
|  |  |  | NPI#:   |
| State License#   | DFA#:  | Practice/  | Facility Name:  |
|  |  |  | City:   |
|  |  |  |   |
|  |  |  | rax Number:   |
|  | Cont   |  |   |
| INSURANCE INFORMATION  | N (Please fax copy of prescript  | ion/medical insurance o  | cards with this form, front and back)   |
| Is the Patient Insured? $\square$ Yes $\square$ No   |  |  |   |
| Policy Holder's Name:  | Policy H   | Iolder's DOB:  | Relationship to Patient:<br>Group #:  |
| Medical Insurance:   | Telephone:   | Policy ID:   | Group #:  |
| Prescription Insurance:  |  | Prescription Plar  | n Telephone:<br>RX PCN #:   |
| Check how if nation t is enrolled in   | manufacturer conav assistance  | KA BIN #<br>If yes, please provide I   | D#  |
| 4 DIAGNOSIS AND CLINICAL   |  |  |   |
|  |  |  | only)   |
|  | Diagnosis  | ((CD-10)   | 6 100   |
| B20 Human Immunodeficiency Vi Other Code: Description  |  |  | r for HIV pre-exposure prophylaxis  |
| Patient Clinical Information:  |  |  | -   |
| Allergies:   |  | -  | □ lb □ kg Height: □ in □ cm   |
|  | nticonvulsants (Carbamazepine  |  | obarbital, Phenytoin), antimycobacteri als  |
|  |  |  |   |

|  |  |   | nd Patient Clinical Information  Patient Phone:   |  |  |
|--|--|---|---|--|--|
| rescriber Name:  | Patient DOB: Patient Phone: Prescriber Phone: To therapy Continuation of therapy: Date of last treatment// |   |   |  |  |
| reatment status: New t                                 | to therapy 🗌 Continuation of thera   | py: Date  | of last treatment//   |  |  |
|  |  |   |   |  |  |
| PRESCRIPTION INFO                                      | <b>DRMATION</b> (to be completed by  | prescrib  | er only)  |  |  |
| MEDICATION   | STRENGTH   |   | DOSE & DIRECTIONS   | QUANTITY/REFILLS                               |  |
| Apretude   |  |   |   |  |  |
| ☐ Apretude 600 mg<br>Injection Kit                     | 600 mg/3mL single-dose vial of cabotegravir  | into the  | ding dose (Month 1 & Month 2): Inject 3 mL<br>muscle at month 1 and month 2, then every 2<br>thereafter | Quantity: 1 dosing kit<br>Refills: 1           |  |
| Apretude 600 mg<br>Injection Kit                       | 600 mg/3mL single-dose vial of cabotegravir  | ☐ Maintenance dose (Month 4+): Inject 3 mL into the muscle every 2 months   |   | Quantity: 1 dosing kit<br>Refills:             |  |
| Cabenuva   |  | -   |   |  |  |
| Option 1: Every-2-Month [                              | Dosing   |   |   |  |  |
| Cabenuva 600/900 mg Injection Kit                      | 600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine                 | Loading dose (Month 1 & Month 2): Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle once monthly for 2 months then maintenance dose as directed |   | Quantity: 1 dosing kit<br>Refills: <u>1</u>    |  |
| ☐ Cabenuva 600/900 mg<br>Injection Kit                 | 600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine                 | ☐ Maintenance dose (Month 4+): Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle every 2 months   |   | Quantity: 1 dosing kit<br>Refills:             |  |
| Option 2: Every-1-Month D                              | Posing   | 1   |   |  |  |
| Cabenuva 600/900 mg                                    | 600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine                 | Loading dose: Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle on day 1. Follow with maintenance dose in 1 month                               |   | Quantity: 1 dosing kit<br>Refills: <u>None</u> |  |
| ☐ Cabenuva 400/600 mg<br>Injection Kit                 | 400 mg/2 mL single-dose vial of cabotegravir + 600 mg/2 mL single-dose vial of rilpivirine                 | ☐ Maintenance dose: Inject 2 mL of cabotegravir and 2 mL of rilpivirine into the muscle every month   |   | Quantity: 1 dosing kit<br>Refills:             |  |
| -  | ATURE REQUIRED (STAMP  | SIGNA   |   |  |  |
| DAW / May Not Substitute Prescriber's Signature: Date: |  |   | Substitution Permissible  | <b>.</b> .                                     |  |
| Prescriber's Signature:                                | Date:  |   | Prescriber's Signature:   | Date:  |  |

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates.